NodThera
PrivateLast Round
IPO Announced
Mar 27, 2026
Total Funding Raised
$145M
Momentum Score
25 /100
Company Overview
NodThera is a biotechnology company focused on developing medicines to combat diseases associated with chronic inflammation through a pipeline of selective NLRP3 inflammasome inhibitors that reduce pro-inflammatory cytokines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NodThera Comps
Public and private peers based on sector, stage, and business model.
NodThera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO Announced | Mar 27, 2026 | ||||
| Series D | Apr 1, 2025 | ||||
| Series B | Jun 3, 2020 | ||||
| Series A | Jun 25, 2018 | ||||
| Seed | Jul 28, 2016 |
Key People
Founding team and executive leadership
NodThera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Epidarex Capital | Series D, Series A, Series B, Seed |
| F-Prime Capital | Series D, Series A, Series B |
| TD Securities | Series B |
| Blue Owl Capital | Series D |
| 5AM Ventures | Series D, Series B, Series A |
| Novo Holdings | Series D, Series B |
| Sanofi Ventures | Series D, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Clinical and commercial plan for ruvonoflast includes Phase 2 data in July 2026 and launch in early 2029.
- Mar 27, 2026
Completed an IPO round of funding.
NodThera Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NodThera's valuation, stock price, and market status.
